Activation of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Induces Neuronal Differentiation through the Mitogen-activated Protein Kinase Pathway*

Boussad SouttouDagger, Nicole Brunet-De Carvalho, Daniel Raulais, and Marc Vigny§

From INSERM U 440/Université Paris 6, Signalisation et Différenciation Cellulaires dans les Systèmes Nerveux et Musculaire, 17 rue du Fer à Moulin, F-75005 Paris, France

Received for publication, August 11, 2000, and in revised form, December 13, 2000


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Anaplastic lymphoma kinase (ALK) is a novel neuronal orphan receptor tyrosine kinase that is essentially and transiently expressed in specific regions of the central and peripheral nervous systems, suggesting a role in its normal development and function. To determine whether ALK could play a role in neuronal differentiation, we established a model system that allowed us to mimic the normal activation of this receptor. We expressed, in PC12 cells, a chimeric protein in which the extracellular domain of the receptor was replaced by the mouse IgG 2b Fc domain. The Fc domain induced the dimerization and oligomerization of the chimeric protein leading to receptor phosphorylation and activation, thus mimicking the effect of ligand binding, whereas the wild type ALK remained as a monomeric nonphosphorylated protein. Expression of the chimera, but not that of the wild type ALK or of a kinase inactive form of the chimera, induced the differentiation of PC12 cells. Analysis of the signaling pathways involved in this process pointed to an essential role of the mitogen-activated protein kinase cascade. These results are consistent with a role for ALK in neuronal differentiation.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

The common structural features of a receptor tyrosine kinase (RTK)1 include an extracellular ligand binding region, a hydrophobic membrane-spanning segment, and a cytoplasmic domain that carries the catalytic function. Following ligand binding, the RTK dimerizes and autophosphorylates (1). The activated RTK initiates signal transduction cascades through binding of SH2 domain-containing proteins to specific receptor phosphotyrosine residues (2). RTKs can regulate a wide variety of cellular processes involved in cell division, differentiation, survival, and motility. A number of RTKs play essential roles during the development of the nervous system by contributing to neuronal differentiation, survival, and function (reviewed in Ref. 3). Most of these receptors have specific or shared ligands called neurotrophic factors that have been identified (reviewed in Ref. 3). However, for some of them, named orphan receptors, their ligands are still unknown (4-6).

Anaplastic lymphoma kinase (ALK), a novel orphan neuronal receptor, was originally identified as a member of the insulin receptor subfamily of receptor tyrosine kinases that acquires transforming capability when truncated and fused in the t(2;5) chromosomal rearrangement associated with the non-Hodgkin lymphoma (7). This translocation produces a fusion gene that encodes a soluble chimeric transforming protein comprised of the N-terminal portion of the phosphoprotein nucleophosmin (NPM), a highly conserved RNA-binding nucleolar protein, linked to the cytoplasmic portion of ALK (7). The NPM-ALK fusion protein was localized within both the cytoplasm and the nucleoplasm and also within the nucleoli of t(2;5)-translocation-positive lymphoma cells (8). However, whereas the NPM sequence is essential for the transforming activity (9), the nuclear localization, occurring via the shuttling activity of NPM (10), is not required for oncogenesis (11). It has been demonstrated that the NPM portion was responsible for the dimerization of the fusion protein leading to the constitutive activation of the kinase and to the transforming activity (8).

Human and mouse cDNAs encoding full-length ALK have been characterized (5, 6). The deduced amino acid sequences revealed that ALK is a novel RTK having an extracellular domain, a single transmembrane domain, and an intracellular domain containing the tyrosine kinase activity. The open reading frame encodes a 1620-amino acid protein that is most closely related to leukocyte tyrosine kinase (4, 12). Surface labeling studies indicated that the mature form of the receptor is a 200-kDa glycoprotein exposed at the cell membrane (5), consistent with the prediction that ALK serves as the receptor for yet unidentified ligand(s). In situ hybridization analysis showed that ALK RNA is essentially and transiently expressed in specific regions of the central and peripheral nervous systems such as the thalamus, mid-brain, olfactory bulb, and peripheral ganglia and that it localizes mostly in neuronal cells (5). The neonatal brain showed the highest expression, suggesting a possible involvement of ALK in development of the nervous system when axon sprouting and retraction are occurring. Because ALK expression is maintained, albeit at a lower level, in the adult brain, it may also play a role in synapse formation and maintenance (5). Thus, ALK is a novel orphan receptor tyrosine kinase that might play an important role in the normal development and function of the nervous system.

The ligand of ALK is unknown. Therefore, to investigate whether ALK can play a role in neuronal differentiation, we generated a constitutively active transmembrane form of ALK by substituting the extracellular domain of the receptor by the Fc fragment of mouse IgG 2b. We show here that the ALK.Fc protein expressed in PC12 cells dimerized, oligomerized, and was tyrosine-phosphorylated. Furthermore, we show that transient expression of ALK.Fc induced neuronal differentiation through the mitogen-activated protein (MAP) kinase pathway.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reagents-- PD98059 was obtained from New England BioLabs (Beverly, MA). Wortmannin was from Sigma (St. Quentin Fallavier, France). ET-18-OCH3 was purchased from Calbiochem (San Diego, CA). Nerve growth factor (NGF) was from Life Technologies (Cergy Pontoise, France) and basic fibroblast growth factor (bFGF) was a gift from F. Mascarelli (INSERM U450, Paris). Rabbit anti-ALK antibody was purchased from Accurate Chemicals Co. (Westbury, NY). Horseradish peroxidase-conjugated anti-mouse IgG was from Dako (Copenhagen, Denmark). Goat anti-P-MAPK antibody was obtained from UBI (Lake Placid, NY). Rabbit anti-phosphotyrosine antibody was from Transduction Laboratories (Lexington, KY). Rabbit anti-SCG10 antibody was a gift from S. Ozon (INSERM U440, Paris).

Plasmid Constructions-- The full-length human ALK cDNA in pBluescript was obtained from the American Tissue Culture Collection (ATCC). The cDNA, cut with XhoI-NotI and blunt-ended, was inserted at the EcoRV site of the mammalian expression vector pcDNA3.1 (Invitrogen, Groningen, The Netherlands) generating the pcDNA-ALK.wt construct. The cDNA, 6226 bp, covered the entire coding sequence of the protein. The ATG start codon is located at nucleotide position 912, the sequence coding for the transmembrane domain is located between nucleotides 4020 and 4083, and the stop codon is at position 5774. There is a HincII site at position 1079 and a PshAI site at position 3892. These sites were used to delete a major part of the ALK extracellular domain to generate the pcDNA-ALK.Fc construct (see below).

The 864-bp PstI-EcoRV fragment of the mouse IgG 2b cDNA corresponding to the Fc fragment (GenBankTM accession number MMIGG7) in pBluescript was a gift from Dr. N. Doyen (Institut Pasteur, Paris). To construct the cDNA coding for the chimeric protein (pcDNA-ALK.Fc) containing extracellularly the mouse IgG 2b Fc domain linked to the membrane-spanning segment and the whole cytoplasmic domain of ALK, a polymerase chain reaction product corresponding to the entire sequence of the Fc fragment, flanked at the 5'-region with a HincII site and at the 3'-region with a PshAI site was produced and inserted at the same sites in the pcDNA-ALK.wt with its HincII-PshAI segment deleted.

We prepared a kinase-defective form of the chimera (designated ALK*.Fc, and the corresponding construct was pcDNA-ALK*.Fc) in which the invariant lysine residue located in the ATP-binding portion of the catalytic domain was changed to arginine. This lysine residue, originally identified as residue 210 of the NPM-ALK fusion protein (7, 8), is located at position 1150 in ALK (5, 6). The mutation was generated with the QuikChange site-directed mutagenesis kit (Stratagene Europe, Amsterdam, The Netherlands) using the sense oligonucleotide primer CTGCAAGTGGCTGTGAGGACGCTGCCTGAAGTG (in which the underlined G replaced an A in the non-mutated sequence), together with the corresponding antisense oligonucleotide primer and the pcDNA-ALK.Fc construct as the template. This single base mutagenesis was verified by sequencing (Genset, Paris, France).

Cell Culture and Electroporation-- The PC12 rat pheochromocytoma cell line (13), purchased from ATCC, was grown, unless otherwise specified, in RPMI 1640 supplemented with 10% horse serum and 5% fetal calf serum at 37 °C in an atmosphere containing 5% CO2.

PC12 cells were electroporated using the EasyJect Plus apparatus (Equibio, United Kingdom) as recommended by the manufacturer. Briefly, 5 × 106 cells in 0.8 ml of OptiMEM (Life Technologies) were mixed with 30 µg of DNA and then pulsed (260 V, 950 microfarads). Cells were immediately transferred to fresh culture media and cultivated on gelatin-coated dishes. In experiments involving pharmacological inhibitors and beta -mercaptoethanol, these supplements were added daily along with fresh culture media. For experiments with growth factors, PC12 cells were grown for 48 h in the presence of either 25 ng/ml NGF or 50 ng of bFGF. Cultures were photographed and neurite-bearing cells counted using an inverted microscope after an incubation period of 48 or 72 h, respectively.

Cell Extracts, Immunoprecipitation, and Immunoblotting-- Following electroporation, cells were grown for 48 h in medium with 10% horse serum and 5% fetal calf serum, then for 24 h in medium with only 0.5% horse serum. Cell extracts were prepared by lysing the cells in immunoprecipitation buffer (50 mM Tris-HCl, pH 8, 150 mM NaCl, 0.5% deoxycholic acid, 1% Nonidet P-40, 10% glycerol, 1 mM sodium orthovanadate, 50 mM sodium fluoride, and protease inhibitor mixture). The lysates were cleared by centrifugation and subjected to either immunoprecipitation or immunoblotting.

For immunoprecipitation, 0.5 mg of total proteins was incubated at 4 °C in a rotating shaker with protein A-Sepharose beads on which a rabbit anti-phosphotyrosine antibody had been previously bound. After 4 h of incubation, the beads were washed with lysis buffer and the bound proteins were eluted by boiling for 5 min in SDS-PAGE sample buffer.

For Western blotting, cell extracts (20 µg) or immunoprecipitated material were resolved by SDS-PAGE and transferred to nitrocellulose membranes. After blocking the membranes in phosphate-buffered saline (PBS), 0.1% Tween 20, 5% powdered milk, they were probed with the antibodies at appropriate dilutions for 1 h at room temperature. The blots were then washed in PBS, 0.1% Tween 20 and incubated with the appropriate secondary antibody coupled to horseradish peroxidase (Dako, Glostrup, Denmark) for 1 h. After washing in PBS, 0.1% Tween 20, the proteins were visualized using the ECL system (Amersham Pharmacia Biotech, Buckinghamshire, UK).

Immunofluorescence Staining-- PC12 cells transiently transfected with the different constructs (pcDNA, pcDNA-ALK.wt, pcDNA-ALK.Fc, or pcDNA-ALK*.Fc) were grown on glass coverslips for 72 h, washed in PBS, fixed for 10 min at room temperature with 4% formaldehyde in PBS, and then washed 3 × 5 min with PBS, 50 mM NH4Cl. After 1 h of blocking in PBS, containing 3%BSA, cells were incubated in the same buffer with an FITC-conjugated goat anti-mouse IgG antibody (1/500 dilution; Jackson Laboratories, West Grove, PA) to visualize ALK.Fc- or ALK*.Fc-expressing cells. After washing 5 × 5 min with PBS, cells were mounted in Citifluor (UKC Chemical Laboratory, Canterbury, UK) before viewing on a conventional fluorescence microscope (Provis, Olympus). To analyze and localize SCG10, a rabbit anti-SCG10 antibody was added to the cells after blocking with PBS, 3% bovine serum albumin, 0.05% saponin for 1 h at room temperature. After washing 3 × 5 min with PBS, 0.05% saponin, cells were incubated with an FITC-conjugated anti-rabbit IgG (Jackson Laboratories, West Grove, PA) for 1 h, washed 5 × 5 min in PBS, mounted, and visualized as described above.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Because the ALK ligand is unknown, we generated a constitutively active form of ALK to study the biological function(s) of this receptor. We thus chose a strategy in which the extracellular domain of ALK was substituted by the mouse IgG 2b Fc domain that we expected would dimerize the resulting chimeric protein through disulfide bond formation between cysteine residues of the Fc domain.

Fig. 1 shows the structures of the pcDNA-ALK.wt, pcDNA-ALK.Fc, and pcDNA-ALK*.Fc constructs. The pcDNA-ALK.wt construct encodes the membrane-bound wild type receptor (see introduction and below). The pcDNA-ALK.Fc construct codes for a transmembrane protein that contains the 30 N-terminal amino acids of ALK, the Fc fragment and a juxtamembrane portion of the extracellular domain (42 amino acids), the transmembrane, and the entire intracellular domains of ALK. The pcDNA-ALK*.Fc construct codes for a kinase-defective form of the chimera in which the invariant lysine residue located in the ATP-binding portion of the catalytic domain was changed to arginine (see "Materials and Methods"). This point mutation has been previously shown to completely inhibit the transforming capability of NPM-ALK (8).


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic representation of the pcDNA-ALK.wt, pcDNA-ALK.Fc, and pcDNA-ALK*.Fc constructs. Diagram shows the positions of the HincII and PshAI sites used to delete a portion of the pcDNA-ALK.wt encoding the extracellular domain and to insert the Fc fragment to generate the pcDNA-ALK.Fc construct. The site of mutagenesis leading to inactivation of the kinase in the ALK*.Fc construct through substitution of the lysine residue of the ATP-binding portion of the catalytic domain for an arginine is indicated by an asterisk (see "Materials and Methods" and Ref. 8). EC, extracellular domain; TK, tyrosine kinase domain; TM, transmembrane domain; SS, signal sequence.

Expression of ALK.Fc and ALK.wt in PC12 Cells-- The pcDNA-ALK.wt and the pcDNA-ALK.Fc constructs were transiently expressed in PC12 cells, and the proteins they encoded were analyzed by SDS-PAGE and Western blotting with anti-ALK antibody or anti-mouse IgG (Fig. 2). Under both reducing and nonreducing conditions, the ALK.wt receptor migrated as a single 200-kDa band, in agreement with previous reports (5). In contrast, the ALK.Fc protein migrated as a single band of 120 kDa under reducing conditions and mainly as a doublet of about 240 and 360 kDa under nonreducing conditions. The 120-kDa band is consistent with that of the predicted 965-amino acid protein encoded by the pcDNA-ALK.Fc construct, whereas the 240- and 360-kDa proteins detected in nonreducing conditions correspond probably to dimers and oligomers (at least trimers), respectively. It is important to note that the anti-ALK antibody detected both the ALK.wt and the ALK.Fc proteins, whereas the anti-mouse IgG revealed only the ALK.Fc protein. These results indicate that the ALK receptor existed as a monomer and that the Fc fragment allowed the ALK.Fc chimera to dimerize and oligomerize through disulfide bond formation.


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 2.   Expression, dimerization, and oligomerization of the ALK.Fc protein. 20 µg of cell extract from PC12 cells transiently electroporated with pcDNA3.1, pcDNA-ALK.wt, or pcDNA-ALK.Fc were resolved by SDS-PAGE under reducing and nonreducing conditions. Proteins were detected by Western blotting with either an anti-ALK antibody (top panel) or an anti-mouse IgG antibody (bottom panel). Note that, although ALK.Fc was detected as monomers under reducing conditions and as both dimers and oligomers under nonreducing conditions, ALK.wt was detected only as monomers under both conditions.

Expression ALK.Fc Induced Neuronal Differentiation of PC12 Cells-- PC12 cells transiently expressing the pcDNA-ALK.Fc construct exhibited neurite extensions, whereas cells expressing the pcDNA-ALK.wt construct, or those that were transfected with the pcDNA-ALK*.Fc vector or the empty pcDNA3 vector, did not (Fig. 3A). The neurites were visible as soon as 24 h post-electroporation and reached the size of severalfold the cell body size at 48 h post-electroporation. To visualize cells overexpressing the ALK.Fc protein, immunofluorescence staining was performed with an FITC-conjugated goat anti-mouse IgG. As shown in Fig. 3B, only neurite-bearing cells stained with the antibody and were therefore expressing ALK.Fc. Immunostaining for the neuronal marker SCG10 (Fig. 3C) revealed an increased expression and a perinuclear localization of the protein (probably in the Golgi network) of the neurite-bearing cells as previously demonstrated for PC12 cells induced to differentiate with NGF (14, 15). In contrast, cells expressing the ALK*.Fc kinase-inactive form of the chimera ALK.Fc failed to extend neurites, although they clearly expressed the corresponding protein, as demonstrated by immunostaining with FITC-conjugated goat anti-mouse IgG (Fig. 3B). One can note that the staining appeared concentrated at the periphery of the transfected cells, suggesting a plasma membrane localization of the protein. No specific immunoreactivity was detected in cells electroporated with both the pcDNA vector or the pcDNA-ALK.wt construct (not shown).


View larger version (68K):
[in this window]
[in a new window]
 
Fig. 3.   Induction of neuronal differentiation by ALK.Fc but not ALK.wt or ALK*.Fc. A, morphological appearance of pcDNA-, pcDNA-ALK.wt-, pcDNA-ALK.Fc-, and pcDNA-ALK*.Fc-electroporated PC12 cultures at 48 h post-electroporation. Note the presence of neurites only in pcDNA-ALK.Fc-electroporated cultures (scale bar, 500 µm). B, immunostaining of ALK.Fc- and ALK*.Fc-expressing cells with an anti-mouse IgG (scale bars, 100 µm). C, immunofluorescence analysis of SCG10 expression and phase contrast microscopy in ALK.Fc-transfected cells. Note the increased expression and perinuclear localization of SCG10 in cells bearing neurites (scale bar, 100 µm).

When cells transiently transfected with the pcDNA-ALK.Fc construct were maintained in the presence of 500 µM of the reducing agent beta -mercaptoethanol, the neurite extension process was almost completely blocked (Fig. 4, A and B). This indicated that the neurite outgrowth process was due to ALK.Fc receptor dimerization and oligomerization through disulfide bond formation, because neurite extension stimulated by either bFGF or NGF was not affected by the presence of beta -mercaptoethanol in the culture medium. These results demonstrate that overexpression of ALK.Fc induced neuronal differentiation of PC12 cells.


View larger version (61K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of ALK.Fc-induced neuronal differentiation by beta -mercaptoethanol. A, morphological appearance of pcDNA-ALK.Fc-electroporated or NGF- and bFGF-treated PC12 cells grown in the absence or the presence of beta -mercaptoethanol. NGF, bFGF, and beta -mercaptoethanol were used, respectively, at concentrations of 25 ng/ml, 50 ng/ml, and 500 µM. Photomicrographs were taken 48 h after electroporation or addition of the indicated of growth factor. B, quantification of neurite outgrowth. Results represent the mean ± S.D. of the number of neurite-bearing cells per high power field in a typical experiment performed in triplicate. Only cells with neurites longer than at least twice the diameter of the cell body were scored as positive. Cell counting was performed 72 h after electroporation and growth in the presence or the absence of beta -mercaptoethanol. 5 to 10 high power fields were counted per dish.

We were unable to isolate stable transfectants from pcDNA-ALK.Fc-transfected cultures, probably because sustained activation of ALK leads essentially to neuronal differentiation and not to cell proliferation in PC12 cells. However, we easily isolated stable transfectants from pcDNA-ALK.wt cultures (not shown). These cells could be good tools for the isolation of the ALK ligand(s) and for further studies on the neurotrophic activity of ALK.

ALK.Fc-induced PC12 Neuronal Differentiation Was Blocked by the MEK-1 Inhibitor PD98059-- To analyze the signal transduction cascade involved in the neuronal differentiation process induced by ALK.Fc, we used pharmacological inhibitors targeting the major signaling pathways coupled to RTKs. The MEK1 (a MAP kinase kinase) inhibitor PD98059, at a concentration of 10 µM, completely blocked the neurite outgrowth process induced by ALK.Fc (Fig. 5, A and B). In contrast, the Phosphoinositide-3 kinase (PI3K) inhibitor wortmannin and the phospholipase Cgamma (PLCgamma ) inhibitor ET-18-OCH3, used at their active concentrations, 20 nM for each inhibitor, had no apparent effect on this process (Fig. 5, A and B). Thus, these data indicate that the PC12 neuronal differentiation induced by ALK.Fc involves mainly the MAP kinase pathway.


View larger version (59K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of signal transduction inhibitors on ALK.Fc-induced neuronal differentiation. A, morphological appearance of control and treated pcDNA-ALK.Fc-electroporated PC12 cells at 48 h post-electroporation. B, quantification of neurite outgrowth. Cell counting was performed as described in Fig. 4, 72 h after electroporation and growth in the presence or the absence of the indicated inhibitor. The MEK1, PI3K, and PLCgamma inhibitors (PD98059, wortmannin, ET-18-OCH3) were added 2 h after electroporation and used at concentrations of 10 µM, 20 nM, and 20 nM, respectively. Addition of another PI3K inhibitor, Ly290042, gave results similar to those of wortmannin (data not shown).

Expression of ALK.Fc Induced Tyrosine Phosphorylation and Activation of the MAP Kinases ERK1 and ERK2-- To determine whether ALK.Fc was autophosphorylated and tyrosine phosphorylated downstream signaling molecules, cell extracts from PC12 cells transiently electroporated with the empty vector, the pcDNA-ALK.wt, or the pcDNA-ALK.Fc constructs were subjected to immunoprecipitation with a rabbit anti-phosphotyrosine antibody, and the immunoprecipitated proteins were visualized by Western blotting with the same antibody. Although the ALK.Fc protein was highly tyrosine-phosphorylated, the ALK.wt protein showed no apparent phosphorylation (Fig. 6A), indicating that dimerization and/or oligomerization of the receptor via the Fc fragment induced its autophosphorylation on tyrosines. Several other tyrosine-phosphorylated proteins, most probably downstream signaling molecules, with molecular masses in the range 50-110 kDa coimmunoprecipitated with ALK.Fc (Fig. 6A).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 6.   Induction of tyrosine phosphorylation and of MAP kinase phosphorylation by ALK.Fc. A, tyrosine phosphorylation of ALK.Fc (p-ALK.Fc) and downstream kinases (arrowheads) as assessed by immunoprecipitation of lysate from pcDNA-, pcDNA-ALK.wt-, or pcDNA-ALK.Fc-electroporated PC12 cells and subsequent Western blotting with a rabbit anti-phosphotyrosine antibody. B, ERK1 and ERK2 phosphorylation detection by Western blotting with an anti-phospho-MAP kinase in lysates from the same cells. pERK1, phosphorylated ERK1; pERK2, phosphorylated ERK2.

To confirm the activation of the MAP kinase cascade by ALK.Fc, cell extracts from PC12 cells transiently electroporated by the empty vector, the pcDNA-ALK.wt, or the pcDNA-ALK.Fc DNAs were analyzed by immunoblotting with an anti-phospho-MAP kinase antibody (i.e. an antibody reacting with the active forms of MAP kinases). The results in Fig. 6B show indeed that the amount of active forms of the MAP kinases (phospho-ERK1 and -ERK2) were higher in cell extracts from PC12/ALK.Fc cells than in extracts from PC12/ALK.wt and PC12/pcDNA cells. Thus activation of the ALK receptor induced by the Fc fragment led to the activation of the MAP kinase pathway.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

ALK is a novel orphan receptor tyrosine kinase that is essentially and transiently expressed in the nervous system (mostly in neuronal cells), suggesting an important role for this receptor during normal development and function of the nervous system. However, because the ligand of this receptor has not yet been identified, the normal biological functions of ALK `are still unknown. In particular, it remains to be shown whether it could act as a functional membrane receptor and whether activation of its kinase activity could induce neuronal differentiation.

To answer these questions, and to study the signal transduction pathways involved in the potential neurotrophic activity of ALK, we established a model system that allowed us to mimic the normal activation of this receptor. We generated an ALK.Fc chimera containing extracellularly the mouse IgG 2b Fc domain linked to the membrane-spanning segment and the whole cytoplasmic domain of ALK and expressed it into PC12 cells. PC12 cells are a widely used and well established in vitro model system for the study of neuronal differentiation, because they can differentiate to neuron-like cells upon exposure to neurotrophic factors (16). The ALK.Fc chimera expressed in PC12 cells had, under reducing conditions, an apparent molecular mass of about 120 kDa, which was in good agreement with that of the predicted 965-amino acid protein encoded by the pcDNA-ALK.Fc construct. In agreement with previous reports (5, 6) the wild type ALK appeared as a 200-kDa protein. As expected, this strategy led to a forced dimerization and oligomerization of the chimera induced by inter-chain disulfide bridges of the Fc domains, whereas the ALK.wt did not dimerize or oligomerize. Western blot studies showed that ALK.Fc was hyperphosphorylated on tyrosines, whereas ALK.wt was not, indicating that the dimerized receptor was activated. To our knowledge, this is the first time that this strategy has been used to produce a constitutively activated form of a RTK. Thus it could be applied to other RTKs but also to other types of membrane-bound receptors that need to be dimerized and/or oligomerized as a first step of their activation.

Transient expression of the pcDNA-ALK.Fc construct in PC12 cells, but not of the pcDNA-ALK.wt and pcDNA-ALK*.Fc constructs, induced neurite extensions in a large majority of ALK.Fc-expressing cells, indicating a direct relationship between expression of the chimeric receptor and the biological effect observed. The neurite extension process was visible as soon as 24 h post-electroporation, consistent with the time necessary for high expression of the oligomerized receptor. This process was specifically induced by dimerization and oligomerization of the chimeric receptor, because inhibition of disulfide bond formation strongly prevented neurite extensions induced by ALK.Fc but did not affect those induced by NGF or bFGF. In parallel to the morphological differentiation, overexpression of ALK.Fc induced expression and localization of the neuronal marker SCG10 in a pattern similar to that induced by NGF (14, 15). The fact that the expression of the ALK*.Fc kinase-inactive form of the chimera did not induce neurite outgrowth practically eliminates the possibility that the dimerized constitutively active form (ALK.Fc) simply serves as a docking site for some other kinase that could be responsible for the effect observed with ALK.Fc. The neuronal differentiation induced by the ALK.Fc expression is due to the intrinsic activation of the kinase activity of this chimera.

Additional proof for the specificity of the neurite elongation process driven by ALK.Fc in PC12 cells was given by transient expression of the pcDNA-ALK.Fc construct in epithelial COS cells. COS cells electroporated with pcDNA-ALK.Fc expressed similar levels of phosphorylated dimerized and oligomerized ALK.Fc chimera than PC12 cells but did not exhibit any neurite-like extensions (data not shown).

It has been reported that ectopic expression of the insulin (17), epidermal growth factor (EGF) (18), and platelet-derived growth factor (19) receptors induced neuronal differentiation of PC12 cells only when they are activated by their cognate ligands. In agreement with these results, overexpression of the wild type ALK did not induce neuronal differentiation of PC12 cells, this receptor being monomeric and inactive in the absence of its ligand. In contrast, the ALK.Fc was permanently active. Altogether, these reports and our data stress the importance of the activation of the tyrosine kinase activity of the RTKs for the neuronal differentiation of PC12 cells.

The cytoplasmic molecules that mediate downstream signaling by ALK are presently unknown. However, analysis of the amino acid sequence of the intracellular portion of ALK revealed potential sites for binding of substrates such as Shc, PI3K, rasGAP, IRS1, Grb2, and PLCgamma (5). Coimmunoprecipitation studies with the NPM-ALK revealed a physical association of the fusion protein with IRS1, Grb2, Shc, and PLCgamma (9, 20). Mutants of NPM-ALK that were defective for binding to and phosphorylation of Shc or IRS-1 could transform NIH3T3 (9) cells, indicating that these signaling molecules are not essential for cell transformation. Finally, PLCgamma appeared to be an important downstream target of NPM-ALK that contributes to its mitogenic activity and is likely to be important in the pathogenesis of large-cell anaplastic lymphomas, since knock-out of this single pathway was sufficient to significantly impair NPM-ALK-mediated oncogenicity in lymphocytes (20).

Using pharmacological inhibitors of the classic pathways coupled to RTKs, we found that the ALK.Fc-induced neurite extension process requires the MAP kinase but not the PI3K and PLCgamma activities. Studies at the molecular level confirmed the activation of the MAP kinase pathway, because the amount of active forms of EKR1 and ERK2 was found to be higher in PC12 cells expressing the pcDNA-ALK.Fc construct versus the pcDNA-ALK.wt construct. Thus, these results indicated for the first time that the MAP kinase pathway can be involved in ALK signaling and that it was necessary for the promotion of neurite extension induced by this receptor.

In addition, these data call several remarks:

First of all, sustained activation of the MAP kinase signaling cascade seems to be essential for the differentiation processes induced by various neurotrophic factors in PC12 cells (21). For instance, stimulation of PC12 cells with NGF or bFGF led to sustained activation of MAP kinase and to neuronal differentiation (22). In contrast, stimulation of the same cells with insulin or EGF triggered transient activation of MAP kinase and did not lead to neuronal differentiation but to cell proliferation (22-25). Nevertheless, when insulin or EGF receptors were overexpressed, sustained activation of MAP kinase and neuronal differentiation was obtained with the respective ligands (17, 18), indicating that the level of receptor expression is critical for the induction of a marked and sustained activation of MAP kinase and neuronal differentiation. In our experiments, the constitutive activation of ALK.Fc probably led to sustained activation of MAP kinase. The fact that we were able to detect MAP kinase activation as late as 72 h post-electroporation supports this assertion.

Second, the PI3K pathway has been shown to be nonessential for neuronal differentiation (26) and has been proposed to be required for the prevention from apoptosis (27) but not for neurite extension (28, 29) promoted by NGF. Thus, these results are consistent with our data showing that PI3K is not involved in the neurite extension induced by ALK.Fc.

Third, mutations at either the PLCgamma or Shc binding site on TrkA (the high affinity NGF receptor) showed no defects in NGF-induced neurite outgrowth and MAP kinase activation, but mutations at both sites did (30). These results indicate that both PLCgamma and Shc trigger the MAP kinase cascade and that they can substitute for each other in NGF signaling. In agreement with our data, these results point to a pivotal role of the MAP kinase cascade in neuritogenesis and can explain why the sole inhibition of PLCgamma activity with ET-18-OCH3 did not block the neurite extension process induced by ALK.Fc. Therefore, it seems that PLCgamma activation is crucial for the mediation of the oncogenic potential of NPM-ALK (see above) (20) but nonessential for the neuronal differentiating activity of ALK.

In conclusion, our results showed that activation of the ALK receptor tyrosine kinase led to neuronal differentiation and this differentiating effect was mainly achieved through the MAP kinase signaling pathway. Thus, these results suggest that ALK could be involved in neuronal differentiation and present the first example for a biological role assigned to ALK.

    ACKNOWLEDGEMENTS

We thank Dr. N. Doyen (Institut Pasteur, Paris) for providing us with the mouse IgG2b cDNA. We are grateful to M. Lambert for helpful discussions and to Drs. A. Sobel and R. Rotundo for comments on the manuscript.

    FOOTNOTES

* This work was supported in part by institutional funding from INSERM and Université Paris 6, as well as by grants from the Association pour la Recherche sur le Cancer (ARC).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Received a postdoctoral fellowship from ARC during this work.

§ To whom correspondence should be addressed: INSERM U 440, 17 rue du Fer à Moulin, F-75005 Paris, France. Tel.: 33-1-45-87-61-35; Fax: 33-1-45-87-61-32; E-mail: vigny@ifm.inserm.fr.

Published, JBC Papers in Press, December 19, 2000, DOI 10.1074/jbc.M007333200

    ABBREVIATIONS

The abbreviations used are: RTK, receptor tyrosine kinase; ALK, anaplastic lymphoma kinase; MAP kinase, mitogen-activated protein kinase; PI3K, phosphoinositide-3 kinase; PLCgamma , phospholipase Cgamma ; NPM, nucleophosmin; NGF, nerve growth factor; bFGF, basic fibroblast growth factor; bp, base pair(s); PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; FITC, fluorescein isothiocyanate; ERK1/2, extracellular signal-regulated kinase 1 and 2; MEK, mitogen-activated protein kinase/ERK kinase; EGF, epidermal growth factor.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203-212[Medline] [Order article via Infotrieve]
2. Pawson, T. (1995) Nature 373, 573-580[CrossRef][Medline] [Order article via Infotrieve]
3. Henderson, C. E. (1996) Curr. Opin. Neurobiol. 6, 64-70[CrossRef][Medline] [Order article via Infotrieve]
4. Ben-Neriah, Y., and Bauskin, A. R. (1988) Nature 333, 672-676[CrossRef][Medline] [Order article via Infotrieve]
5. Morris, S. W., Naeve, C., Mathew, P., James, P. L., Kirstein, M. N., Cui, X., and Witte, D. P. (1997) Oncogene 14, 2175-2188[CrossRef][Medline] [Order article via Infotrieve]
6. Iwahara, T., Fujimoto, J., Wen, D., Cupples, R., Bucay, N., Arakawa, T., Mori, S., Ratzkin, B., and Yamamoto, T. (1997) Oncogene 14, 439-449[CrossRef][Medline] [Order article via Infotrieve]
7. Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., and Look, A. T. (1994) Science 263, 1281-1284[Medline] [Order article via Infotrieve]
8. Bischof, D., Pulford, K., Mason, D. Y., and Morris, S. W. (1997) Mol. Cell. Biol. 17, 2312-2325[Abstract]
9. Fujimoto, J., Shiota, M., Iwahara, T., Seki, N., Satoh, H., Mori, S., and Yamamoto, T. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 4181-4186[Abstract/Free Full Text]
10. Chan, W. Y., Liu, Q. R., Borjigin, J., Busch, H., Rennert, O. M., Tease, L. A., and Chan, P. K. (1989) Biochemistry 28, 1033-1039[Medline] [Order article via Infotrieve]
11. Borer, R. A., Lehner, C. F., Eppenberger, H. M., and Nigg, E. A. (1989) Cell 56, 379-390[Medline] [Order article via Infotrieve]
12. Bernards, A., and de la Monte, S. M. (1990) EMBO J. 9, 2279-2287[Abstract]
13. Greene, L. A., and Tischler, A. S. (1976) Proc. Natl. Acad. Sci. U. S. A. 73, 2424-2428[Abstract]
14. Stein, R., Orit, S., and Anderson, D. J. (1988) Dev. Biol. 127, 316-325[Medline] [Order article via Infotrieve]
15. DiPaolo, G., Lutjens, R., Pellier, V., Stimpson, S. A., Beuchat, M. H., Catsicas, S., and Grenningloh, G. (1997) J. Biol. Chem. 272, 5175-5182[Abstract/Free Full Text]
16. Teng, K. K., and Greene, L. A. (1994) J. Neurosci. 14, 2624-2635[Abstract]
17. Dikic, I., Schlessinger, J., and Lax, I. (1994) Curr. Biol. 4, 702-708[Medline] [Order article via Infotrieve]
18. Traverse, S., Seedorf, K., Paterson, H., Marshall, C. J., Cohen, P., and Ullrich, A. (1994) Curr. Biol. 4, 694-701[Medline] [Order article via Infotrieve]
19. Vetter, M. L., and Bishop, J. M. (1995) Curr. Biol. 5, 168-178[Medline] [Order article via Infotrieve]
20. Bai, R. Y., Dieter, P., Peschel, C., Morris, S. W., and Duyster, J. (1998) Mol. Cell. Biol. 18, 6951-6961[Abstract/Free Full Text]
21. Marshall, C. J. (1995) Cell 80, 179-185[Medline] [Order article via Infotrieve]
22. Qui, M. S., and Green, S. H. (1992) Neuron 9, 705-717[Medline] [Order article via Infotrieve]
23. Dahmer, M. K., and Perlman, R. L. (1988) Endocrinology 122, 2109-2113[Abstract]
24. Mark, M. D., and Storm, D. R. (1997) J. Biol. Chem. 272, 17238-17244[Abstract/Free Full Text]
25. Hwang, J. J., Kwon, J. H., and Hur, K. C. (1997) Mol. Cells 7, 438-443[Medline] [Order article via Infotrieve]
26. Obermeier, A., Bradshaw, R. A., Seedorf, K., Choidas, A., Schlessinger, J., and Ullrich, A. (1994) EMBO J. 13, 1585-1590[Abstract]
27. Yao, R., and Cooper, G. M. (1995) Science 267, 2003-2006[Medline] [Order article via Infotrieve]
28. Powers, J. F., Shahsavari, M., Tsokas, P., and Tischler, A. S. (1999) Cell Tissue Res. 295, 21-32[CrossRef][Medline] [Order article via Infotrieve]
29. Klesse, L. J., Meyers, K. A., Marshall, C. J., and Parada, L. F. (1999) Oncogene 18, 2055-2068[CrossRef][Medline] [Order article via Infotrieve]
30. Stephens, R. M., Loeb, D. M., Copeland, T. D., Pawson, T., Greene, L. A., and Kaplan, D. R. (1994) Neuron 12, 691-705[Medline] [Order article via Infotrieve]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.